FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM).The regulatory body granted accelerated approval to linvoseltamab under the brand name Lynozyfic for the treatment of R/R MM who have received at least four prior lines of therapy, including a...